Search clinical trials for: Adjuvanted herpes simplex (gD) candidate vaccine GSK 208141

Total 8 results

GlaxoSmithKline

Completed

Humoral and Cellular Immune Response of Herpes Simplex (gD) Candidate Vaccines From 2 Different Cell Lines

Prophylaxis Herpes Simplex

Belgium
GlaxoSmithKline

Completed

Safety Evaluation of Herpes Simplex Candidate Vaccine (gD2t) With Adjuvant in HSV Seropositive / Seronegative Subjects

Prophylaxis for Herpes Simplex

Austria, Germany, Belgium, United States, Australia, Canada, Denmark, France, Puerto Rico, South Africa, Spain, Switzerland
GlaxoSmithKline

Completed

Evaluation of Safety of Candidate gD Vaccine, With or Without MPL in Healthy Herpes Simplex Virus-positive Adults

Herpes Simplex
GlaxoSmithKline

Completed

Evaluation of Immunogenicity, Reactogenicity and Safety of Herpes Simplex (gD) Candidate Vaccine With/Without Adjuvant

Prophylaxis Herpes Simplex

Belgium
GlaxoSmithKline

Completed

Safety of a Herpes Simplex Candidate Vaccine (gD2t) With MPL and Its Efficacy to Prevent Genital Herpes Disease

Herpes Simplex
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of GSK Biologicals Tuberculosis Vaccines (692342) to Healthy Adults

Tuberculosis

Philippines
GlaxoSmithKline

Completed

HerpeVac Trial for Young Women

Herpes Simplex Infection

United States, Canada
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.

Malaria | Malaria Vaccines

Ghana

3

Subscribe